Rodes Biopharma ApS: Financial statements 2023
CVR: 42425990
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Rodes Biopharma ApS (CVR 42425990) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 1,773,764 and a net result of DKK 386,985 compared with DKK 389,813 the year before. That is an increase of 264.4% compared with the year before. Equity in the 2023 report amounted to DKK 522,822. The solvency ratio was 35.8%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,773,764
- Profit/Loss
- DKK 386,985
- Equity
- DKK 522,822
- Total Assets
- DKK 1,459,351
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Rodes Biopharma ApS has published its annual report for 2022. Gross profit came to DKK 486,825, and the net result was DKK 389,813.
About Rodes Biopharma ApS
Rodes Biopharma ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Rodes ApS. The management consists of Jens Bo Rode Hansen. The board consists of Gitte Rode. The company is owned by Jens Bo Rode Hansen and Gitte Rode. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 3,592,336 and a net result of DKK 1,503,450 compared with DKK 93,839 the year before. Equity in the 2025 report amounted to DKK 1,863,111.